Superior immunogenicity of seasonal influenza vaccines containing full dose of MF59 (R) adjuvant Results from a dose-finding clinical trial in older adults

摘要

Background: MF59-adjuvanted influenza vaccines have superior immunogenicity in older adults compared with non-adjuvanted vaccines. We assessed whether changing formulation (i.e., increasing H3N2 antigen or decreasing the quantity of adjuvant) of the licensed, MF59-adjuvanted trivalent influenza subunit vaccine Fluad(R) (Novartis Vaccines and Diagnostics) improves the risk-benefit profile in vaccinees aged >65 years.